Biotechnology
A collection of 9 posts
Avecho Biotechnology Limited (AVE) - Clinical-Stage CBD Drug Development With Funding Constraints
Target: $0.0006 | Outlook: NEGATIVE | Downside: -88%
· Ryan Lim
Alterity Therapeutics Limited (ATH) - Clinical-Stage Biotech With Positive Phase 2 Results
Target: A$0.023 | Outlook: POSITIVE | Upside: 109%
· Ryan Lim
Skin Elements Limited (SKN) - Early Commercialization Despite Critical Liquidity Challenges
Target: $0.0031 | Outlook: NEUTRAL | Upside: 3%
· Ryan Lim
Opthea Limited (OPT) - Advancing Phase 3 Trials with Manufacturing Validation
Target: $8.80 | Outlook: POSITIVE | Upside: 47%
· Ryan Lim
Invion Limited (IVX) - Clinical-Stage Biotech Facing Critical Funding Challenges
Target: $0.14 | Outlook: NEGATIVE | Upside: -30%
· Ryan Lim
Imugene Limited (IMU) - Clinical-Stage Immuno-Oncology Development
Target: $0.0426 | Outlook: POSITIVE | Upside: 9.2%
· Ryan Lim
Imagion Biosystems Limited (IBX) - Restructuring Pre-Commercial Cancer Diagnostics Company
Target: $0.042 | Outlook: POSITIVE | Upside: 83%
· Ryan Lim
Anatara Lifesciences Ltd (ANR) - Clinical-Stage Biotech Approaching Phase II Results
Target: $0.072 | Outlook: POSITIVE | Upside: 44%
· Ryan Lim
Dimerix Limited (DXB) - Advancing Phase 3 FSGS Treatment Through Regional Partnerships
Target: $0.38 | Outlook: NEUTRAL | Upside: -1%
· Ryan Lim